Researchers create programmable immune cells for next-generation cancer therapy

Researchers at the Masonic Cancer Center, University of Minnesota, including Martin Felices, PhD, Jeffrey S. Miller, MD, and first author Rih-Sheng Huang, PhD, have developed a highly efficient genome editing platform that could improve how natural killer (NK) cells are engineered for cancer immunotherapy.  The approach allows scientists to precisely reprogram immune cells with built-in genetic circuits designed to help the cells better target, survive, and respond to cancer within difficult tumor environments.

NK cells are a type of immune cell capable of recognizing and killing cancer cells.  Because they carry a lower risk of complications such as graft-versus-host disease, researchers have increasingly explored them as promising candidates for “off-the-shelf” cellular therapies that could be manufactured in advance and used across multiple patients.

However, engineering NK cells has historically been challenging.  Many existing approaches rely on viral delivery systems that can insert genetic material into unpredictable locations within cells, potentially leading to inconsistent gene expression and safety concerns.  The new platform was designed to address these limitations by enabling more precise and scalable engineering of NK cells for therapeutic applications.

Addressing the limits of current NK cell engineering

Although NK cells show strong promise for cancer immunotherapy, engineering them for therapeutic use has remained a significant challenge.  Existing approaches often struggle with low genome editing efficiency, toxicity caused by inserted DNA, and poor survival of cells after the editing process.  These limitations make it difficult to reliably manufacture large numbers of functional NK cells for clinical use.

Many current engineering methods also rely on viral delivery systems that insert genetic material into cells at random locations within the genome.  This can lead to inconsistent expression of genes and raises potential safety concerns.  In contrast, the University of Minnesota team focused on a non-viral precision editing approach designed to deliver genetic material into NK cells while preserving the cells’ strength and function after editing.

Rather than forcing immune cells to continuously express genes, the researchers designed systems that could respond dynamically to cellular and environmental conditions.  By leveraging the cells’ own internal regulatory programs, the team aimed to create engineered NK cells capable of adapting their activity based on signals within the tumor environment.

Building programmable immune cells

Using the new platform, the researchers demonstrated they could efficiently insert genetic material into NK cells while maintaining strong cell recovery after editing.  In some experiments, the system achieved insertion efficiencies approaching 90 percent, representing a substantial improvement over many previous non-viral engineering approaches.  The team also showed that the platform could support scalable manufacturing workflows compatible with clinical production.

Beyond improving editing efficiency, the researchers explored how engineered NK cells could be programmed with more adaptive immune functions.  The team developed multiple engineered systems designed to enhance cancer targeting, persistence, and resistance to tumor escape, a process in which cancer cells evade treatment by changing or losing specific markers recognized by immune cells.  These included dual-targeting chimeric antigenic receptor (CAR) systems capable of recognizing more than one cancer marker, as well as engineered IL-15 signaling systems designed to help NK cells survive and remain active longer within the body.

The researchers also redesigned an immune checkpoint pathway known as CISH to strengthen NK cell activity and support sustained signaling.  In another part of the study, the team engineered NK cells with a hypoxia-responsive system that activates under low-oxygen conditions commonly found within tumors. When triggered, the system produces IL-12, an immune signaling protein that helps support NK cell activity in harsh tumor conditions.

Fluorescent microscopy image showing Granzyme B, a protein involved in cancer cell killing, within a genetically engineered human natural killer (NK) cell.  Masonic Cancer Center, University of Minnesota researchers used precision genome editing to visualize the protein in living NK cells for the first time.

Enhancing NK cell performance against cancer

The engineered NK cells demonstrated long-term function, cancer cell killing, and adaptability across multiple laboratory and animal models.  Researchers showed that the platform could support complex therapeutic designs while maintaining high editing efficiency and strong post-editing recovery, helping address longstanding barriers in NK cell engineering.

Several engineered NK cell systems improved the ability to target and eliminate cancer cells, including lymphoma, leukemia, and ovarian cancer.  Dual-targeting CAR systems helped reduce the risk of tumor escape by recognizing more than one cancer marker, while NK cells engineered through the CISH pathway demonstrated stronger antitumor activity and improved survival outcomes in animal models.  The researchers also found that the engineered NK cells retained strong cancer-killing ability under low-oxygen conditions commonly found within tumors.  In addition, the platform supported large-scale manufacturing workflows capable of producing billions of edited NK cells for potential clinical use.

Expanding the future of engineered cancer therapies

The findings highlight the potential for a new generation of engineered immune cell therapies that are more adaptable, precise, and scalable for clinical use.  By enabling NK cells to respond dynamically to signals within the tumor environment, the platform moves beyond conventional approaches that rely on static or continuously active therapeutic systems.

The ability to produce billions of edited NK cells at clinical scale could help support more accessible “off-the-shelf” cellular therapies while allowing increasingly sophisticated designs tailored to different cancer settings.

Although additional validation and clinical testing will be needed, the study provides a framework for developing more controlled and responsive cancer immunotherapies.  Future research will continue exploring how programmable NK cell systems can be refined to improve durability, safety, and effectiveness across a wider range of cancers.